EDF announces the success of its inaugural “Kangaroo” senior multi tranche bond issuance for a nominal amount of AUD 1 billion On 21 August 2025: EDF (BBB positive S&P / Baa1 stable Moody’s / BBB+ negative Fitch) successfully priced its inaugural “Kangaroo” senior bond issuance in 2 tranches for a nominal amount of AUD 1 billion (the “Bonds”): AUD 500 million Bond, with a 10-year maturity and a 5.636% fixed coupon;AUD 500 million Bond, with a 20-year maturity and a 6.627% fixed coupon. This transaction ena ...

Core Insights - The Group's CEO Bjørn Hembre and Interim CFO Edvin Aspli will present the second quarter results on August 21, 2025, at 9:00 Icelandic time [1] - Icelandic Salmon is dual-listed on Euronext Growth in Oslo and NASDAQ First North in Reykjavík, indicating a broad market presence [1] - The Group owns 100% of Arnarlax ehf, a fully integrated farming company in Iceland, controlling the entire value chain from egg to market delivery [1] Company Overview - Icelandic Salmon operates a fully integrated business model, ensuring quality control across all stages of production [1] - The head office of Arnarlax ehf is located in Bíldudalur, Iceland, emphasizing its local operational focus [1] - The Group's commitment to transparency is reflected in its adherence to the Norwegian Securities Trading Act for disclosure requirements [2]

Core Viewpoint - ALK reported a strong Q2 performance with a 12% organic revenue growth and a 41% increase in operating profit, leading to an upgraded full-year revenue outlook [1][6]. Q2 Performance Highlights - Revenue for Q2 2025 reached DKK 1,527 million, reflecting a 12% growth in local currency and an 11% growth in reported currency [3]. - Operating profit (EBIT) for Q2 was DKK 375 million, marking a 41% increase in local currency and a 42% increase in reported currency, with an EBIT margin of 25% [3]. - For H1 2025, revenue totaled DKK 3,049 million, with a consistent 12% growth in both local and reported currencies [3]. Financial Highlights - Full-year revenue outlook has been upgraded to a growth expectation of 12-14% in local currencies, previously estimated at 9-13% [6][13]. - Tablet sales grew by 16% to DKK 831 million, with Europe and North America showing significant growth rates of 17% and 32%, respectively [6]. - Sales of Other products and services increased by 30% to DKK 215 million, while anaphylaxis revenue surged by 56% [6]. Strategic Initiatives - The launch of new products, including the house dust mite tablet and the neffy adrenaline nasal spray, has exceeded initial market expectations [7][8]. - A dedicated pediatric sales force in the USA has been fully deployed, contributing to growth initiatives [7][8]. - Patient recruitment for the clinical phase 2 trial with the peanut allergy tablet was completed ahead of schedule [7].

Core Insights - Nicox SA announced positive results from the Phase 3 Denali trial for NCX 470, demonstrating non-inferiority in lowering intraocular pressure (IOP) compared to latanoprost [1][4][5] - The trial involved 696 patients and showed IOP reductions of 7.9 to 10.0 mmHg for NCX 470 versus 7.1 to 9.8 mmHg for latanoprost [1][5] - NCX 470 is expected to be submitted for New Drug Applications (NDAs) in the U.S. and China in H1 2026 [4][7] Company Overview - Nicox is an international ophthalmology company focused on innovative solutions for ocular health, with NCX 470 as its lead product candidate [16] - The company has established partnerships with Kowa and Ocumension Therapeutics to facilitate NDA preparations and potential future strategies [7][16] - Nicox's revenue streams include royalties from various products, including ZERVIATE® and VYZULTA® [16] Clinical Trial Details - The Denali trial was a randomized, multi-regional, double-masked study comparing NCX 470 0.1% to latanoprost 0.005% [10][11] - The primary efficacy evaluation was based on IOP reduction at multiple time points, confirming the efficacy profile required for regulatory submissions [11][14] - The trial also included a long-term safety extension, with NCX 470 showing a favorable safety profile [6][11] Financial Implications - Nicox will receive a €5 million milestone payment from Kowa based on the trial results, with potential royalties starting at 8% on net sales in the U.S. [12] - Total potential milestones under the agreement with Kowa are valued at €127 million [12] - Royalties of 6% to 12% on net sales are expected from the Chinese, Korean, and Southeast Asian markets due to the partnership with Ocumension [13]

Multitude Capital Oyj publishes its H1 2025 ReportHelsinki, 21 August 2025 – Multitude Capital Oyj (the “Company”), a wholly-owned subsidiary of Multitude AG, announced today the publication of its Half-Year 2025 Report, encompassing the Interim Board of Directors and the Condensed Interim Financial Statements as at 30 June 2025. Key figures, EUR’0001 January - 30 June 2025 6 June - 30 June 2024Net interest income614(64)Profit / (loss) before income tax495(141)Net cash flow from operating activities<td styl ...

Core Viewpoint - Sampo plc has initiated a share buyback program with a maximum value of EUR 200 million, which commenced on 7 August 2025, following the authorization from its Annual General Meeting on 23 April 2025 [1][2]. Group 1: Share Buyback Details - On 20 August 2025, Sampo plc acquired a total of 323,763 A shares at a daily weighted average price of EUR 9.96 [1]. - The buyback transactions were executed across multiple markets, including AQEU, CEUX, TQEX, and XHEL, with respective volumes of 7,235, 125,148, 34,713, and 156,667 shares [1]. - The total number of Sampo A shares owned by the company after the transactions is 3,275,016, representing 0.12% of the total shares outstanding [2].

Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025 report. The full report is available at the Company’s website: www.herantis.com. Antti Vuolanto, CEO of Herantis, said: “We made significant clinical progress in the first half of 2025, advancing HER-096 through the Phase 1b study which is now approaching completion on schedule, a key milestone. We reported encoura ...

Core Insights - VGP NV reported a pre-tax profit of €208.6 million for H1 2025, marking a 35% increase compared to H1 2024, driven by net rental income and valuation gains [2] - The company achieved a total committed annualized rental income of €441.3 million, reflecting a 7% year-to-date increase and 14.7% organic growth year-over-year [2] - VGP's total investment property at share increased by 8.3% to €5.4 billion, with a balance sheet total surpassing €5 billion [2] Financial Performance - Net rental and renewable energy income rose by 24.3% to €40.9 million, while joint venture management fee income increased by 2.6% to €16.1 million [2] - Net valuation gains on the portfolio reached €141.5 million, representing a 42.8% increase [2] - On a look-through basis, net rental income increased by 16.4% compared to H1 2024, totaling €103.9 million [2] Leasing and Development - VGP signed and renewed lease agreements totaling €56.1 million, covering 822,000 sqm during H1 2025 [2] - The pre-let ratio for assets under construction is currently at 76%, with projects older than six months achieving an 80% pre-let rate [2] - The company delivered 11 projects totaling 264,000 sqm during H1 2025, achieving a 96.3% let rate [2] Land Acquisition and Development Potential - VGP acquired 633,000 sqm of development land, expanding into the UK and several other European countries [2] - The total secured landbank now stands at 9.7 million sqm, with a development potential exceeding 4 million sqm, estimated to generate over €256 million in rental value [2] Renewable Energy Initiatives - Gross renewable income surged by 71.5% year-over-year to €6.5 million, with total renewable energy capacity installed increasing from 143 MW to 177.3 MW [2] - Marketable production of renewable energy rose from 47 GWh to 70 GWh, reflecting a 49% year-over-year increase [2] Financial Stability and Outlook - The company has available liquidity of €0.9 billion and extended the maturity of outstanding financial indebtedness through bond issuances totaling €576 million [2] - VGP's EPRA NTA increased by 4.8% since December 2024 and by 11.5% year-over-year [2] - The company received an investment grade BBB- rating from Standards & Poor's with a stable outlook [2]

Group 1 - The company, Vantage Drilling International Ltd., will host a conference call on August 28, 2025, at 10:00 AM Eastern Time to discuss its operating results for the second quarter of 2025 [1] - Earnings will be released before the conference call on the same day and will be available on the company's website [1] - Vantage is an offshore drilling contractor that primarily contracts drilling units and related services to oil and gas companies globally [4] Group 2 - The company provides management services for third-party-owned drilling units in addition to its primary business [4] - Contact information for the Chief Financial Officer, Rafael Blattner, is provided for further inquiries [5] - Instructions for accessing the conference call include a registration process and options for joining the call [6]

Core Viewpoint - SalMar ASA has announced a share buyback program aimed at facilitating the delivery of shares to employees as part of its share-based incentive programs [1][2]. Group 1: Share Buyback Program Details - The share buyback program will start on 21 August 2025 and conclude no later than 30 September 2025 [2]. - The program allows for the purchase of up to 100,000 shares, with a maximum expenditure of NOK 65 million [2]. - DNB Carnegie has been appointed to manage the share repurchases, making trading decisions independently of SalMar [3]. Group 2: Regulatory Compliance - The share buyback will be conducted in accordance with Regulation (EU) No 596/2014 and Commission Delegated Regulation (EU) No 2016/1052 [3]. - The company retains the right to modify the terms of the program and will announce any changes accordingly [4].